ClinicalTrials.gg
Active, not recruitingNCT05266105Updated Nov 24, 2025

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

A Phase 1 interventional study of Palazestrant and Palbociclib in Breast Cancer, sponsored by Olema Pharmaceuticals, Inc.. Active, not recruiting at 8 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Olema Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Breast Neoplasms with a site in Australia — 84 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Enrollment
307th of 380
60 · median 253
Started
2021
with 19 others
Phase 1
72 of 402
23 open now
Primary completion
2026-03
later than 37 of 155 live
Registered
291st of 402
by date
Lead sponsor
6 of 402
Olema Pharmaceuticals, Inc.

Among the 402 studies in Breast Neoplasms with a site in Australia, this one is the 307th largest by enrollment of the 380 interventional ones that give a count, is one of 20 that started in 2021, is one of 72 in phase 1, reaches primary completion later than 37 of the 155 other live ones, and was the 291st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

84 of the 402 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed and evaluable locally advanced or breast cancer
  • (ECOG) performance status of 0 or 1
  • Must not have received prior oral endocrine or targeted therapy ≤ 2 weeks prior to first dose
  • Must not have received prior chemotherapy, antibody therapy, or therapy ≤ 4 weeks prior to the first dose
  • Prior radiotherapy must have been completed 2 weeks prior to first dose
  • Adequate safety laboratory tests
  • Willingness to use effective

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal disease
  • Significant hepatic disease
  • Significant cardiovascular disease
  • Significant abnormalities
  • History of pulmonary embolism or high risk of thrombosis
  • Known infection
  • Active infection (requiring antimicrobial therapy)
  • Pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily with Palbociclib in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer

    Drug: Palazestrant · Drug: Palbociclib

  • Experimental
    Dose Expansion

    This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 in combination with Palbociclib and estimates preliminary data of anti-tumor efficacy

    Drug: Palazestrant · Drug: Palbociclib

Interventions

  • Complete Estrogen Receptor Antagonist

    Also known as: OP-1250

  • Palbociclib is an approved CDK 4/6 Inhibitor drug

    Also known as: Ibrance®️

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities

    Time frame: From Cycle 1 Day 1 through C1 Day 28

  2. Characterization and Incidence in Adverse Events and Serious Adverse Events

    Time frame: From initial inform consent date through 30 days post last dose

  3. Plasma levels of OP-1250 and Palbociclib

    Time frame: Up to 9 months

07

Study locations

8 sites
  • Clinical Trial Site
    Waratah, New South Wales 2298, Australia
  • Clinical Trial Site
    Westmead, New South Wales 2145, Australia
  • Clinical Trial Site
    South Brisbane, Queensland 4101, Australia
  • Clinical Trial Site
    Southport, Queensland 4215, Australia
  • Clinical Trial Site
    Clayton, Victoria 3168, Australia
  • Clinical Trial Site
    Frankston, Victoria 3199, Australia
  • Clinical Trial Site
    Geelong, Victoria 3220, Australia
  • Clinical Trial Site
    Nedlands, Western Australia 6009, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2026, 51 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 51 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Mar 4, 2022
StartActual
Dec 10, 2021
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05266105
Lead sponsor
Olema Pharmaceuticals, Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Dec 10, 2021
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Sue Johnson
study director · Olema Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palazestrant

Start the discussion